Jawad Haider Butt, ESC 2022: A post hoc analysis of PARAGON-HF assessing sacubitril/valsartan in patients with HFpEF according to frailty status
The post hoc analysis of PARAGON-HF assessed the efficacy of sacubitril/valsartan, compared with valsartan, according to frailty status in patients with heart failure (HF) with preserved fraction (HFpEF). Frailty is a common issue, with patients less likely to receive pharmacological therapy due to a less favourable benefit/risk profile. In this touchCARDIO interview, we speak with Dr Jawad Haider Butt (Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark) to discuss the post-hoc analysis of PARAGON-HF data and the impact of patient frailty on clinical outcomes.
The abstract entitled ‘Efficacy and safety of sacubitril/valsartan according to frailty in heart failure with preserved ejection fraction: a post hoc analysis of the PARAGON-HF trial’ was presented at the European Society of Cardiology (ESC) Congress 2022, 26 – 29 August 2022.
- What are the challenges in the treatment of frail patients with heart failure (HF)? (0:18)
- Can you give us an overview of the PARAGON-HF trial? (2:00)
- Could you tell us a little about the post-hoc analysis of PARAGON-HF data, and the parameters used to assess frailty? (2:44)
- How were clinical outcomes affected by patient frailty? (4:05)
- What did the PARAGON-HF teach us about the efficacy and safety of sacubitril/valsartan, in patients with HF with preserved fraction (HFpEF)? (5:03)
- How can these findings be used to optimise treatment decisions in patients with HFpEF? (6:08)
Disclosures: Jawad Haider Butt is on the advisory board for Bayer.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Danielle Crosby.
Filmed as a highlight of ESC 2022
Access more content on Heart Failure here
Share this Video
Related Videos In Heart Failure
Gregg Stone, ACC 2023: COAPT trial results – Transcatheter edge-to-edge repair with MitraClip device for functional mitral regurgitation in heart failure
The COAPT trial investigated the use of the MitraClip a novel device for patients with secondary mitral regurgitation, a condition in which blood leaks backward through the mitral valve into the left atrium of the heart. In this touchCARDIO interview Dr Gregg Stone (Mount Sinai Heart Health System, New York City, NY, USA) discusses the […]
John Boehmer, ACC 2023: MicrocorTM device for heart failure management, the BMAD trial
The BMAD trial investigated patients with heart failure assessed the use of the Microcor device on readmission rates. In this touchCARDIO interview, we speak with Dr John Boehmer (Penn State Milton S Hershey Medical Center, Penn State College of Medicine, Hershey, PA, USA) to discuss purpose, findings and clinical implications of the BMAD trial in […]
John Boehmer, ACC 2023: The MicrocorTM device, monitoring tool for heart failure
The most common cause of hospital admission due to heart failure is due to excess fluid retention. The MicrocorTM device monitors fluid levels in the lungs to aid in patient management. In this touchCARDIO interview, we speak with Dr John Boehmer (Penn State Milton S Hershey Medical Center, Penn State College of Medicine, Hershey, PA, […]
Journal articles and more to your inbox
Get the latest clinical insights from touchCARDIOSign me up!